Coherus Oncology (CHRS) Net Margin (2013 - 2026)

Coherus Oncology has disclosed Net Margin across 13 years of filings, most recently posting 144.2% for Q2 2026.

• In Q2 2026, Net Margin fell 304811.0% year-over-year to 144.2%; the TTM figure through Jun 2026 stood at 259.41% (down 82756.0% YoY), while the FY2025 annual figure was 489.61%, up 21018.0% from the prior year.
• Net Margin came in at 144.2% for Q2 2026 at Coherus Oncology, up from 311.35% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 4457.32% in Q1 2024 to a low of 744.43% in Q1 2025.
• Average Net Margin over 5 years is 199.43%, with a median of 152.02% recorded in 2022.
• Year-over-year, Net Margin soared 469079 bps in 2024 and sank 520175 bps in 2025.
• Over 5 years, Net Margin stood at 129.81% in 2022, then soared by 33 bps to 87.03% in 2023, then sank by 653 bps to 655.58% in 2024, then soared by 55 bps to 295.29% in 2025, then surged by 51 bps to 144.2% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 144.2% in Q2 2026, 311.35% in Q1 2026, and 295.29% in Q4 2025.